Altimmune (ALT) AI Stock Analysis

• Market Cap: $371.47M
• Dividend Yield: N/A
• Average Volume (3M): 8.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -95.12%
• EPS Growth: 21.09%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 81,106,970
• 10 Day Avg. Volume: 17,103,178
• 30 Day Avg. Volume: 8,521,127
• PEG Ratio: -0.99
• Price to Book (P/B): 3.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.10
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 1.04K
• Enterprise Value/Gross Profit: -12.71K
• Enterprise Value/Ebitda: -1.32
• 1Y Price Target: $17.75
• Price Target Upside: 303.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 50 Neutral
• Price Target: $5.00 ▲(13.64%Upside)

Altimmune's overall stock score reflects significant challenges in financial performance and valuation, offset by positive earnings call guidance and a strong balance sheet. Technical indicators suggest a bearish trend, but potential growth in new therapeutic areas and financial flexibility provide some optimism.

Positive Factors

MASH treatment potential

Pemvidutide showed a robust treatment effect on MASH resolution with a response rate significantly higher than placebo.

Phase 3 advancement

The high likelihood of moving to Phase 3 is supported by precedents where similar drugs moved forward despite missing the fibrosis endpoint.

Weight loss benefits

Pemvidutide produced weight loss of up to 6.2% at 24 weeks, with a continued downward trajectory and no evidence of plateauing.

Negative Factors

Clinical development risks

Risks include clinical development risk tied to pemvidutide, competitor risk in relevant therapeutic areas, and capital market and dilution risk.

Development challenges

There are challenges for ALT to execute the full clinical development program required to bring pemvidutide to market.

Stock rating and price target

The stock is recommended at a Sell rating with a significant downside to the price target.

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in the areas of liver disease and immune modulating therapies. The company is headquartered in Gaithersburg, Maryland, and is actively working on a pipeline that includes treatments for non-alcoholic steatohepatitis (NASH), obesity, and infectious diseases. Altimmune leverages its proprietary technologies to develop vaccines and therapies that aim to improve patient outcomes.

How the Company Makes Money

Altimmune primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue streams consist of research and development collaborations, government contracts, and potential future product sales. Altimmune has previously received funding through government contracts for its infectious disease programs and may enter into partnerships with other pharmaceutical companies to co-develop or license its therapies. These partnerships can provide milestone payments and royalties, contributing to the company's revenue. Additionally, as its drug candidates progress through clinical trials, Altimmune may secure additional funding through equity offerings to support its operations and research initiatives.

Altimmune Financial Statement Overview

Summary

Altimmune faces significant challenges in achieving profitability and positive cash flow, reflected in the negative margins and cash flow metrics. However, the company maintains a strong balance sheet with low leverage, providing a cushion for future growth opportunities.

Income Statement

Altimmune has shown inconsistent revenue figures over the years, with a significant drop in the most recent period. Gross profit margins have been volatile, and the company has consistently posted negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 88.65% in the latest period, reflecting a solid balance sheet with minimal debt. The debt-to-equity ratio is favorable, indicating low financial leverage. However, the persistent net income losses have impacted the return on equity, which remains negative.

Cash Flow

Altimmune has experienced negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, reflecting the company's difficulties in translating earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.00K	20.00K	426.00K	-68.00K	4.41M	8.19M
Gross Profit	-41.00K	20.00K	-51.00K	-568.00K	3.86M	-25.32M
EBITDA	-90.75M	-94.81M	-87.94M	-84.40M	-96.53M	-54.15M
Net Income	-90.24M	-95.06M	-88.45M	-84.71M	-97.09M	-49.04M
Balance Sheet
Total Assets	157.26M	139.31M	210.64M	206.93M	218.86M	245.12M
Cash, Cash Equivalents and Short-Term Investments	149.83M	131.89M	197.81M	184.88M	190.30M	215.92M
Total Debt	0.00	1.68M	671.00K	1.12M	1.53M	1.82M
Total Liabilities	15.10M	15.80M	16.54M	21.64M	19.73M	19.24M
Stockholders Equity	142.16M	123.51M	194.10M	185.29M	199.13M	225.88M
Cash Flow
Free Cash Flow	-80.33M	-79.85M	-75.86M	-62.71M	-90.55M	-34.65M
Operating Cash Flow	-80.33M	-79.85M	-75.81M	-62.59M	-78.24M	-34.44M
Investing Cash Flow	6.03M	-28.39M	13.73M	-73.40M	87.52M	-72.09M
Financing Cash Flow	44.42M	10.04M	86.11M	56.78M	65.10M	213.49M

Altimmune Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Negative. The current price of 4.4 is below the 20-day moving average (MA) of 5.65, below the 50-day MA of 5.62, and below the 200-day MA of 6.43, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 41.10 is Neutral, neither overbought nor oversold. The STOCH value of 61.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALT.

Altimmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	78 Outperform	$656.26M	15.30	20.50%	―	2333.50%	―
AUTL	53 Neutral	$657.37M	―	-49.91%	―	-14.16%	25.88%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
ALT	50 Neutral	$371.47M	―	-57.28%	―	-95.12%	21.09%
IVA	44 Neutral	$448.70M	―	344.74%	―	-47.32%	-26.67%
ORIC	43 Neutral	$888.89M	―	-48.45%	―	―	7.15%
SANA	33 Underperform	$913.50M	―	-71.44%	―	―	19.94%

Altimmune Corporate Events

Altimmune Announces Positive Phase 2b Trial Results

On June 26, 2025, Altimmune announced positive topline results from its IMPACT Phase 2b trial of pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The trial showed significant MASH resolution and weight loss in participants treated with pemvidutide compared to placebo, with low discontinuation rates due to adverse events. These results suggest pemvidutide’s potential as a transformative therapy for MASH, a condition with limited current treatment options, and support further progression to Phase 3 trials.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Altimmune Secures $100 Million Credit Facility

On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.